2011 - 2016

2016

• Porzine Circovirus Typ 2 (PCV2) - Infektionen in oberbayerischen Schweinemastbeständen mit routinemäßiger Impfung gegen PCV2. -Bedeutung für das Auftreten von Lungenveränderungen bei Schlachttierkörpern-.
  Nicoll I., Striegl J., Fux R., Sutter G., Ritzmann M., Eddicks M.
  Tierärztl. Umschau, 71(10), 360-370 (2016)
• Non-plaque-forming virions of Modified Vaccinia virus Ankara express viral genes. (pdf, 843 KB)
  Lülf A.T., Freudenstein A., Marr L., Sutter G., Volz A.
  Virology, 499, 322-330 (2016)
• Increased protein degradation improves influenza Virus nucleoprotein-specific CD8+ T cell activation in vitro but not in C57BL/6 mice. (pdf, 1,83 MB)
  Altenburg A.F., Sandt C.E. van de, Trierum S.E. van, Gruyter H.L. De, Run P.R. van, Fouchier R.A., Roose K., Saelens X., Volz A., Sutter G., Vries R.D. de, Rimmelzwaan G.F.
  J. Virol., 90(22), 10209-10219 (2016)
• Anti-apoptotic Bcl-XL but not Mcl-1 contributes to protection against virus-induced apoptosis. (pdf, 702 KB)
  Ohmer M., Weber A., Sutter G., Ehrhardt K., Zimmermann A., Häcker G.
  Cell Death Dis., 7(8):e2340 (2016) doi: 10.1038/cddis.2016.242.
• T-and B-cell responses to multivalent prime-boost DNA and viral vectored vaccine combinations against hepatitis C virus in non-human primates. (pdf, 1,06 MB)
  Rollier C.S., Verschoor E.J., Verstrepen B.E., Drexhage J.A., Paranhos-Baccala G., Liljeström P., Sutter G., Arribillaga L., Lasarte J.J., Bartosch B., Cosset F.L., Inchauspe G., Heeney J.L.
  Gene Ther., 23(10), 753-759 (2016)
• Low pathogenic avian influenza (H9N2) in chicken: Evaluation of an ancestral H9-MVA vaccine. (pdf, 1,03 MB)
  Ducatez M., Becker J., Freudenstein A., Delverdier M., Delpont M., Sutter G., Guerin J.-L., Volz A.
  Vet. Microbiol., 189, 59-67 (2016)
• Low prevalence of porcine circovirus type 2 infections in farrowing sows and corresponding pre-suckling piglets in southern German pig farms. (pdf, 485 KB)
  Eddicks M., Koeppen M., Willi S., Fux R., Reese S., Sutter G., Stadler J.,
  Ritzmann M.
  Vet. Microbiol., 187, 70-74, (2016)
• CCL2 expression is mediated by type I IFN receptor and recruits NK and T cells to zhe lung during MVA infection. (pdf, 1,26 MB)
  Lehmann M.H., Torres-Dominquez L.E., Price P.J.R., Brandmüller C., Kirschning C.J., Sutter G.
  J. Leukoc. Biol., 99(6), 1057-1064 (2016)
• Immunogenicity and protective efficacy of recombinant Modified Vaccinia virus Ankara candidate vaccines delivering West Nile virus envelope antigens. (pdf, 1,75 MB)
  Volz A., Lim S., Kaserer M., Lülf A., Marr L., Jany S., Deeg C.A., Pijlman G.P., Koraka P., Osterhaus A.D.,
  Martina B.E., Sutter G.
  Vaccine, 34(16), 1915-1926 (2016)
• Myristoylation increases the CD8+ T cell response to a GFP prototype antigen delivered by modified vaccinia virus Ankara. (pdf, 1,05 MB)
  Marr L., Lülf A.T., Freundenstein A., Sutter G., Volz A.
  J. Gen. Virol., 97, 934-940 (2016)
• Rusa alfredi papillomavirus 1 -a novel deltapapillomavirus inducing endemic papillomatosis i the endangered Visayan spotted deer. (pdf, 4,18 MB)
  Fux R., Langenmayer M.C., Jörgens D., Schubert C., Heckel J-O., Sutter G.
  J. Gen. Virol., 97(1), 128-133 (2016)
• In Vivo Killing Capacity of Cytotoxic T Cells Is Limited and Involves Dynamic Interactions and T Cell Cooperativity. (pdf, 3,77 MB)
  Halle S., Keyser K.A., Stahl F.R.,  ..., Sutte G., Messerle M., Förster R.
  Immunity, 44(2), 233-245 (2016)
• An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels.
  (pdf, 12,3 MB)
  Haagmans B.L., Brand J.M.A. van den, Raj S.V., Volz A., Wohlsein P., Smits S.L., Schipper D., Bestebroer T.M., Okba N., Fux R., Bensaid A., Solanes Foz D.S., Kuiken T., Baumgärtner W., Segales J., Sutter G.,
  Osterhaus A.D.M.E.
  Science, 351(6268), 77-81 (2016)

2015

• Modifiziertes Vacciniavirus Ankara (MVA) - die Entwicklung als Vektorimpfstoff und Einsatzmöglichkeiten in der Veterinärmedizin. (pdf, 1,43 MB)
  Volz A., Fux R., Langenmayer M.C., Sutter G.
  Berl. Münch. Tierärztl. Wochenschr., 128(11/12), 464-472 (2015)
• Protective efficacy of recombinant Modified Vaccinia vurus Ankara delivering Middle East respiratory syndrome coronavirus spike glycoprotein. (pdf, 1,84 MB)
  Volz A., Kupke A., Song F., Jany S., Fux R., Shams-Eldin H., Schmidt J., Becker C., Eickmann M., Becker S., Sutter G.
  J. Virol., 89(19), 8651-8656 (2015)
• Induction of influenza (H5N8) antibodies by modified vaccinia virus Ankara H5N1 vaccine. (pdf, 470 KB)
  Vries R.D. de, Gruyter H.L.M. De, Bestebroer T.M., Pronk M., Fouchier R.A.M., Osterhaus A.D.M.E., Sutter G., Kreijtz J.H.C.M., Rimmelzwaan G.F.
  Emerg. Infect. Dis., 21(6), 1086-1088 (2015)
• Use of the LC16m8 smallpox Vaccine in immunocompromised individuals is still too risky. (pdf, 100 KB)
  Danon Y.L., Sutter G.
  Clin. Vaccine Immunol., 22(5), 604 (2015)
• Detection of a new cluster of porcine circovirus type 2b strains in domestic pigs in Germany. (pdf, 4,92 MB)
  Eddicks M., Fux R., Szikora F., Eddicks L., Majzoub-Altweck M., Hermanns W., Sutter G., Palzer A., Banholzer E., Ritzmann M.
  Vet. Microbiol., 176(3-4), 337-343 (2015)
• Modified vaccinia virus Ankara but not vaccinia virus induces chemokine expression in cells of the monocyte/macrophage lineage. (pdf, 992 KB)
  Lehmann M.H., Price P.J.R., Brandmüller C., Sutter G.
  Virology J., 12, 21 (2015)
• Complement component C5 recruits neutrophils in the absence of C3 during respiratory infection with modified vaccinia virus Ankara. (pdf, 389 KB)
  Price P.J.R., Banki Z., Scheideler A., Stoiber H., Verschoor A., Sutter G., Lehmann M.H.
  J. Immunol., 194(3), 1164-1168 (2015)
  
• A single immunization with modified vaccinia virus Ankara-based influenza virus H7 vaccine affords protection in the Influenza A(H7N9) pneumonia ferret model. (pdf, 705 KB)
  Kreijtz J.H.C.M., Wiersma L.C.M., Gruyter H.L.M. De, Vogelzang-van Trierum S.E., Amerongen G. van, Stittelaar K.J., Fouchier R.A.M., Osterhaus A.D.M.E., Sutter G., Rimmelzwaan G.F.
  J. Infect. Dis., 211(5), 791-800 (2015)

2014

• Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influeza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trial. (pdf, 276 KB)
  Kreijtz J.H.C.M., Goeijenbier M., Moesker F.M., Dries L. van den, Goeijenbier S., Gruyter H.L.M. De, Lehmann M.H., Mutsert G. de, Vijver D.A.M.C. van de, Volz A., Fouchier R.A.M., Gorp E.C.M. van, Rimmelzwaan G.F., Sutter G., Osterhaus A.D.M.E.
  Lancet Infect. Dis., 14(12), 1196-1207 (2014)
  
• Recombinant modified vaccinia virus Ankara expressing glycoprotein E2 of Chikungunya virus protects AG129 mice against lethal challenge. (pdf, 1,71 MB)
  Doel P. van den, Volz A., Roose J.M., Sewbalaksing V.D., Pijlman G.P., Middelkoop I. van, Duiverman V., Wetering E. van de, Sutter G., Osterhaus A.D.M.E., Byron M.E.E.
  PLOS Neglected Tropical Diseases, 8(9), e3101 (2014)
• Modified vaccinia virus Ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseases. (pdf, 817 KB)
  Altenburg A.F., Kreijtz J.H.C.M., Vries R.D. de, Song F., Fux R., Rimmelzwaan G.F., Sutter G., Volz A.
  Viruses, 6(7), 2735-2761 (2014)
• Rapit expansion of CD8+ T cells in wild-type and type I interferon receptor deficient mice correlates with protection after low-dose emergency immunization with modified vaccinia virus Ankara. (5,22 MB)
  Volz A., Langenmayer M., Jany S., Kalinke U., Sutter G.
  J. Virol., 88(18), 10946-10957 (2014)
• Chemokine (C-C motif) receptor 1 (CCR1) is required for efficient recruitment of neutrophils during respiratory infection with modified vaccinia virus Ankara. (pdf, 2,96 MB)
  Price P.J., Luckow B., Torres-Dominguez L.E., Brandmüller C., Zorn J., Kirschning C.J., Sutter G., Lehmann M.H.
  J. Virol., 88(18), 10840-10850 (2014)
• IL-17-induced CXCL12 recruits B cells and induces follicle formation in BALT in the absence of differentiated FDCs. (pdf, 2,17 MB)
  Fleige H., Ravens S., Moschovakis G.L., Bölter J., Willenzon S., Sutter G., Häussler S., Kalinke U., Prinz I., Förster R.
  J. Exp. Med., 211(4), 643-651 (2014)

2013

• Middle east respiratory syndrome Coronavirus spike protein delivered by modified vaccinia virus Ankara efficiently induces virus-neutralizing antibodies. (pdf, 155 KB)
  Song F., Fux R., Provacia L.B., Volz A., Eickmann M., Becker S., Osterhaus A.D.M.E., Haagmans B.L., Sutter G.
  Journal of Virology, 87(21), 11950-11954 (2013)
• Vaccination with recombinant modified vaccinia virus Ankara prevents the onset of intestinal allergy in mice.
  (pdf, 835 K)
  Bohnen C., Wangorsch A., Schülke S., Nakajima-Adachi H., Hachimura S., Burggraf M., Süzer Y., Schwantes A., Sutter G., Waibler Z., Reese G., Toda M., Scheurer S., Vieths S.
  Allergy, 68(8), 1021-1028 (2013)
• Poxvirus vectors. (pdf, 152 KB)
  Kreijtz, J.H., Gilbert S.C., Sutter G.
  Vaccine, 31(39), 4217-4219 (2013)
• Protective efficacy of Modified Vaccinia virus Ankara in preclinical studies. (pdf, 269 KB)
  Volz A., Sutter G.
  Vaccine, 31(39), 4235-4240 (2013)
• Modified vaccinia virus Ankara: Innate immune activation and induction of cellular signalling. (pdf, 257 KB)
  Price P.J.R., Torres-Dominquez L.E., Brandmüller C., Sutter G., Lehmann M.H.
  Vaccine, 31(39), 4231-4234 (2013)

• Interleukin-1beta receptor expressed by modified vaccinia virus Ankara interferes with interleukin-1 beta activity produced in various virus-infected antigen-presenting cells. (pdf, 450 KB)
  Zimmerling S., Waibler Z., Resch T., Sutter G., Schwantes A.
  Virol J., 10(1), 34 (2013)

2012

• Easy and efficient protocols for working with recombinant vaccinia virus MVA. (online-abstract)
  Kremer M., Volz A., Kreijtz J.H., Fux R., Lehmann M.H., Sutter G.
  Methods Mol. Biol., 890, 59-92 (2012)

• Critical role of perforin-dependent CD8+ T cell immunity for rapid protective vaccination in a murine model for human smallpox. (pdf, 2,1 MB)
  Kremer M.*, Suezer Y.*, Volz A.*, Frenz T., Majzoub M., Hanschmann K.-M., Lehmann M.H., Kalinke U., Sutter G.
  PLoS Pathogens, 8(3), e1002557 (2012); *equal contribution

• Modified vaccinia virus Ankara delivers a robust surrogate marker for immune monitoring to sarcoma cells even if cells are being exposed to chemotherapy and heat treatment. (pdf, 796 KB)
  Tschoep-Lechner K., Drexler I., Hammer D., Neumann D., Pohla H., Sutter G., Noessner E., Issels R.-D.
  Int. J. Hyperthermia, 28(1), 33-42 (2012)
• Cytosolic DNA triggers mitochondrial apoptosis via DNA damage signaling proteins independently of AIM2 and RNA polymerase III. (pdf, 225 KB)
  Wenzel M., Wunderlich M., Besch R., Poeck H., Willms S., Schwantes A., Kremer M., Sutter G., Endres S.,
  Schmidt A., Rothenfusser S.
  J. Immunology, 188(1), 394-403 (2012)

2011

• Preclinical evaluation of influenza vaccines based on replication-deficient poxvirus vector MVA.
  (pdf, 140 K) 
  Rimmelzwaan G.F., Kreijtz J.H.C.M., Suezer Y., Schwantes A., Osterhaus A.D.M.E., Sutter G.
  Procedia in Vaccinology, 4, 78-83 (2011)

• N1L is an ectromelia virus virulence factor and essential for in vivo spread upon respiratory infection.
  (pdf, 3,1 MB)
  Gratz M. S., Suezer Y., Kremer M., Volz A., Majzoub M., Hanschmann K.-M., Kalinke U., Schwantes A.,
  Sutter G.
  J. Virol., 85(7), 3557-3569 (2011)

• Induction of Noxa-mediated apoptosis by modified vaccinia virus Ankara depends on viral recognition by cytosolic helicases, leading to IRF-3/IFN-ß-dependent induction of pro-apoptotic Noxa. (pdf, 842 KB)
  Ferrer P.E., Potthof S., Kirschnek S., Gasteiger G., Kastenmüller W., Ludwig H., Paschen S.A., Villunger A.,
  Sutter G., Drexler I., Häcker G.
  PLoS Pathog., 7(6), e1002083 (2011)

• Uptake of antigens from modified vaccinia Ankara virus-infected leukocytes enhances the immunostimulatory capacity of dendritic cells. (online-abstract)
  Flechsig C., Suezer Y., Kapp M., Tan SM., Löffler J., Sutter G., Einsele H., Grigoleit GU.
  Cytotherapy, 13(6), 739-752 (2011)